Diferencia entre revisiones de «EBQ:RE-LY»
Sin resumen de edición |
(question and conclusion) |
||
| Línea 15: | Línea 15: | ||
}} | }} | ||
==Clinical Question== | ==Clinical Question== | ||
Is dabigatran (brand name Pradaxa) safe for use in patients with atrial fibrillation when compared to warfarin in terms of stroke and bleeding risks | |||
==Conclusion== | ==Conclusion== | ||
In comparison to warfarin in patients with atrial fibrillation, dabigatran given at a dose of 110 mg demonstrated similar stroke and lower bleeding rates. At 150 mg, dabigatran use was associated with lower rates of stroke and systemic embolism but similar rates of major hemorrhage. | |||
==Major Points== | ==Major Points== | ||
Revisión del 12:18 25 nov 2013
incomplete Journal Club Article
Connolly SJ, et al. "Dabigatran versus warfarin in patients with atrial fibrillation". The New England Journal of Medicine. 2009. 361(12):1139-51.
PubMed Full text PDF
PubMed Full text PDF
Clinical Question
Is dabigatran (brand name Pradaxa) safe for use in patients with atrial fibrillation when compared to warfarin in terms of stroke and bleeding risks
Conclusion
In comparison to warfarin in patients with atrial fibrillation, dabigatran given at a dose of 110 mg demonstrated similar stroke and lower bleeding rates. At 150 mg, dabigatran use was associated with lower rates of stroke and systemic embolism but similar rates of major hemorrhage.